The WOMAN-2 trial is testing tranexamic acid (or TXA), a blood clot stabiliser that was discovered in Japan in the 1950’s, to see if it can prevent excessive bleeding soon after giving birth. TXA is a widely available medicine that is commonly used for other bleeding conditions and works by maintaining the blood clots that prevent bleeding.

The ability to form a blood clot depends on fibrinogen levels. In both trauma and postpartum haemorrhage (PPH), a low serum fibrinogen is a strong predictor of life threatening bleeding. Early TXA administration has the potential to prevent excessive blood loss by reducing fibrinogen depletion. Women with anaemia are at increased risk of bleeding soon after delivery. If they can be treated with TXA before their fibrinogen levels fall, severe postpartum bleeding and its consequences may be prevented.


For more information on Tranexamic Acid, please visit: txacentral.lshtm.ac.uk